The findings support the ongoing Phase 2 ASCEND study strategy of PCRX-201 administered at the 10-fold lower dose (1.4E11 genomic copies [GC]) with corticosteroid pretreatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback